Position in PFE
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$478,782
-$745,253 QoQ
Shares Held
19,883
-54.4% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#1,790
of 2,821 holders
Holding Since
Dec 2022
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in PFE Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Gateway Wealth Partners, LLC holds $15,922,774 across 11 Drug Manufacturers - General names. PFE ranks #8 (3.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
17,158 | $4,317,639 | |
| 2 | LLY |
ELI LILLY & Co
|
2,629 | $3,153,301 | |
| 3 | JNJ |
Johnson & Johnson
|
11,060 | $2,808,908 | |
| 4 | MRK |
Merck & Co., Inc.
|
10,347 | $1,329,589 | |
| 5 | AZN |
Astrazeneca PLC
|
6,327 | $1,199,725 | |
| 6 | AMGN |
Amgen Inc
|
2,558 | $926,302 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
7,305 | $922,913 | |
| 8 | PFE |
Pfizer Inc
This page
|
19,883 | $478,782 |
All Filings in PFE
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $478,782 | 19,883 | Shares | Sole | 2026-08-04 | |
| 2026-03-31 | $1,224,035 | 43,591 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $250,469 | 10,059 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $231,868 | 9,100 | Shares | Sole | 2025-11-06 | |
| 2024-06-30 | $200,784 | 7,176 | Shares | Sole | 2024-08-16 | |
| 2024-03-31 | $251,193 | 9,052 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $274,973 | 9,551 | Shares | Sole | 2024-02-13 | |
| 2023-09-30 | $665,357 | 20,059 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $774,094 | 21,104 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $821,100 | 20,125 | Shares | Sole | 2023-05-10 | |
| 2022-12-31 | $932,004 | 18,189 | Shares | Sole | 2023-02-16 | |
| No filing history on record for this holder in this stock. | ||||||